Form 4: Alnylam Pharmaceuticals Executive Receives Stock Award for 10 Years of Service

Pushkal Garg, CMO & EVP of Development & Medical Affairs at Alnylam Pharmaceuticals, received 96 shares of common stock as a recognition for 10 years of continuous employment.

Summary

• Pushkal Garg, a top executive at Alnylam Pharmaceuticals, received 96 shares of company stock on October 8, 2024, as a reward for completing 10 years of employment.
• The shares were issued as part of a company program that grants USD $50,000 worth of stock to employees upon reaching this milestone, net of the minimum statutory tax liability.
• Garg also indirectly owns 431 shares through a managed account and 250 shares held in a trust where his spouse is a co-trustee.
• He disclaims beneficial ownership of the shares held in trust.

Sentiment

Score: 7

Explanation: The document reflects a positive event (employee recognition) and standard executive compensation practices. There are no indications of negative financial performance or concerning disclosures.

Positives

• The stock award reflects Alnylam's commitment to employee recognition and retention.
• The executive's continued employment suggests confidence in the company's future.

Industry Context

Stock awards are a common practice in the pharmaceutical industry to incentivize and retain key employees. This aligns with industry standards for executive compensation.

Comparison to Industry Standards

• Many pharmaceutical companies, such as Amgen, Gilead Sciences, and Biogen, utilize stock awards and options as part of their executive compensation packages.
• These awards are typically tied to performance metrics and long-term value creation for shareholders.
• The USD $50,000 stock award for 10 years of service is a fairly standard practice for retaining employees.

Stakeholder Impact

• The stock award has a minor positive impact on employee morale.
• The transaction has a negligible impact on shareholders.

Key Dates